117 related articles for article (PubMed ID: 27103202)
1. Soluble VEGF receptor 1 (sFLT1) induces non-apoptotic death in ovarian and colorectal cancer cells.
Miyake T; Kumasawa K; Sato N; Takiuchi T; Nakamura H; Kimura T
Sci Rep; 2016 Apr; 6():24853. PubMed ID: 27103202
[TBL] [Abstract][Full Text] [Related]
2. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic potential of combination therapy of soluble VEGF receptor 1 and conventional chemotherapy for ovarian cancer growth.
Sato N; Kumasawa K; Yamashita M; Miyake T; Nakamura H; Kimura T
J Obstet Gynaecol Res; 2020 Apr; 46(4):636-645. PubMed ID: 32022375
[TBL] [Abstract][Full Text] [Related]
4. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia.
Maynard SE; Min JY; Merchan J; Lim KH; Li J; Mondal S; Libermann TA; Morgan JP; Sellke FW; Stillman IE; Epstein FH; Sukhatme VP; Karumanchi SA
J Clin Invest; 2003 Mar; 111(5):649-58. PubMed ID: 12618519
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in gestational vascular complications.
Yagel S
Thromb Res; 2011 Feb; 127 Suppl 3():S64-6. PubMed ID: 21262445
[TBL] [Abstract][Full Text] [Related]
6. Soluble fms-like tyrosine kinase-1 and soluble endoglin in HIV-associated preeclampsia.
Govender N; Naicker T; Rajakumar A; Moodley J
Eur J Obstet Gynecol Reprod Biol; 2013 Sep; 170(1):100-5. PubMed ID: 23806447
[TBL] [Abstract][Full Text] [Related]
7. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.
Sela S; Itin A; Natanson-Yaron S; Greenfield C; Goldman-Wohl D; Yagel S; Keshet E
Circ Res; 2008 Jun; 102(12):1566-74. PubMed ID: 18515749
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of the PI3K-Akt pathway suppresses sFlt1 expression in human placental hypoxia models in vitro.
Park JK; Jeong JW; Kang MY; Baek JC; Shin JK; Lee SA; Choi WS; Lee JH; Paik WY
Placenta; 2010 Jul; 31(7):621-9. PubMed ID: 20488538
[TBL] [Abstract][Full Text] [Related]
9. A longitudinal study of plasma levels of soluble fms-like tyrosine kinase 1 (sFlt1), placental growth factor (PlGF), sFlt1: PlGF ratio and vascular endothelial growth factor (VEGF-A) in normal pregnancy.
Palm M; Basu S; Larsson A; Wernroth L; Åkerud H; Axelsson O
Acta Obstet Gynecol Scand; 2011 Nov; 90(11):1244-51. PubMed ID: 21568945
[TBL] [Abstract][Full Text] [Related]
10. Lethality in an anti-angiogenic tumor gene therapy model upon constitutive but not inducible expression of the soluble vascular endothelial growth factor receptor 1.
Sivanandam VG; Stephen SL; Hernandez-Alcoceba R; Alzuguren P; Zabala M; van Rooijen N; Qian C; Berger I; Gross ML; Prieto J; Kochanek S
J Gene Med; 2008 Oct; 10(10):1083-91. PubMed ID: 18720430
[TBL] [Abstract][Full Text] [Related]
11. Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia?
Bdolah Y; Lam C; Rajakumar A; Shivalingappa V; Mutter W; Sachs BP; Lim KH; Bdolah-Abram T; Epstein FH; Karumanchi SA
Am J Obstet Gynecol; 2008 Apr; 198(4):428.e1-6. PubMed ID: 18191808
[TBL] [Abstract][Full Text] [Related]
12. Delivery of soluble VEGF receptor 1 (sFlt1) by gene electrotransfer as a new antiangiogenic cancer therapy.
Verrax J; Defresne F; Lair F; Vandermeulen G; Rath G; Dessy C; Préat V; Feron O
Mol Pharm; 2011 Jun; 8(3):701-8. PubMed ID: 21548585
[TBL] [Abstract][Full Text] [Related]
13. Placental Angiogenic Factors Are Associated With Maternal Thyroid Function and Modify hCG-Mediated FT4 Stimulation.
Korevaar TI; Steegers EA; de Rijke YB; Visser WE; Jaddoe VW; Visser TJ; Medici M; Peeters RP
J Clin Endocrinol Metab; 2015 Oct; 100(10):E1328-34. PubMed ID: 26204137
[TBL] [Abstract][Full Text] [Related]
14. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
[TBL] [Abstract][Full Text] [Related]
15. Soluble Flt1 and placental growth factor are novel determinants of newborn thyroid (dys)function: the generation R study.
Korevaar TI; Steegers EA; Schalekamp-Timmermans S; Ligthart S; de Rijke YB; Visser WE; Visser W; de Muinck Keizer-Schrama SM; Hofman A; Hooijkaas H; Bongers-Schokking JJ; Russcher H; Tiemeier H; Jaddoe VW; Visser TJ; Medici M; Peeters RP
J Clin Endocrinol Metab; 2014 Sep; 99(9):E1627-34. PubMed ID: 24885632
[TBL] [Abstract][Full Text] [Related]
16. Aspirin inhibits expression of sFLT1 from human cytotrophoblasts induced by hypoxia, via cyclo-oxygenase 1.
Li C; Raikwar NS; Santillan MK; Santillan DA; Thomas CP
Placenta; 2015 Apr; 36(4):446-53. PubMed ID: 25638730
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of pathological brain angiogenesis through systemic delivery of AAV vector expressing soluble FLT1.
Shen F; Mao L; Zhu W; Lawton MT; Pechan P; Colosi P; Wu Z; Scaria A; Su H
Gene Ther; 2015 Nov; 22(11):893-900. PubMed ID: 26090874
[TBL] [Abstract][Full Text] [Related]
18. Angiogenic factors for the prediction of preeclampsia in high-risk women.
Moore Simas TA; Crawford SL; Solitro MJ; Frost SC; Meyer BA; Maynard SE
Am J Obstet Gynecol; 2007 Sep; 197(3):244.e1-8. PubMed ID: 17826405
[TBL] [Abstract][Full Text] [Related]
19. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
Aref S; El Sherbiny M; Goda T; Fouda M; Al Askalany H; Abdalla D
Hematology; 2005 Apr; 10(2):131-4. PubMed ID: 16019458
[TBL] [Abstract][Full Text] [Related]
20. Serum sFlt1:PlGF ratio, PlGF, and soluble endoglin levels in gestational proteinuria.
Ohkuchi A; Hirashima C; Matsubara S; Suzuki H; Takahashi K; Usui R; Suzuki M
Hypertens Pregnancy; 2009 Feb; 28(1):95-108. PubMed ID: 19165674
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
